<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Genomes2People on Medium]]></title>
        <description><![CDATA[Stories by Genomes2People on Medium]]></description>
        <link>https://medium.com/@genomes2people?source=rss-2971ce165ddd------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*8MEp_O3D5DoEaer9epZeBQ.png</url>
            <title>Stories by Genomes2People on Medium</title>
            <link>https://medium.com/@genomes2people?source=rss-2971ce165ddd------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 10:00:22 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@genomes2people/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Can Genomic Sequencing at Birth Transform Medicine?]]></title>
            <link>https://genomes2people.medium.com/can-genomic-sequencing-at-birth-transform-medicine-e57fe3d54e6a?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/e57fe3d54e6a</guid>
            <category><![CDATA[tedtalks]]></category>
            <category><![CDATA[newborn]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[genomics]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Tue, 09 Dec 2025 20:03:53 GMT</pubDate>
            <atom:updated>2025-12-11T13:39:34.017Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M17SnuuX4ODA0SvvfFKDOg.jpeg" /></figure><h3>Reflections from my TED Talk</h3><p>By <a href="https://www.genomes2people.org/about/director/">Dr. Robert C. Green</a></p><p>This year I was invited onto the TED main stage to share the story of newborn sequencing- and the full 12 minute talk is <a href="http://go.ted.com/robertcgreen">now available to watch</a>.</p><p>Ten years ago, our <a href="https://www.genomes2people.org/research/babyseq/">BabySeq Project</a> sequenced the first newborn in human history. Four years ago, we co-founded the first international consortium pulling together 27 research groups around the world in this space, and just a few weeks ago, we won federal funding for the first nationwide project, the BEACONS initiative, to assess the feasibility of newborn sequencing through public health programs in the U.S. When I spoke about this at TED, I wanted to give people a sense of just how fast this field is moving — and why it matters — right now.</p><h3><strong>Actionable Results are Surprisingly Common</strong></h3><p>In the original BabySeq Project, we found that genomic risk is <a href="https://www.cell.com/ajhg/fulltext/S0002-9297(18)30424-5">far more common</a> than most people realize. Now a second iteration of BabySeq is underway, and as <a href="https://www.genomes2people.org/wp-content/uploads/2024/08/InPress_BabySeq_AJHG_Smith_BabySeq2.pdf">those results</a> begin to come into focus, we have more detail about those risks.</p><p>On the TED stage, I invited the audience to imagine a world where a single test at birth could change the trajectory of a life — and then shared what we’ve discovered so far. If we screen newborns for around 400 genes that are clearly linked to actionable childhood conditions — in other words, conditions with readily available treatments, about 4% of babies carry at least one of those mutations. This is already an attention-getting number, and it’s only going to grow; that list of 400 genes is bound to expand, perhaps drastically, with the continual discovery of more risk mutations and treatments.</p><p>We explored that expansion in BabySeq, looking at a much longer list of 5,000 genes linked to risk mutations that may not be actionable yet, or that may not manifest until adulthood, and found that an astonishing 12% of babies carried at least one of these mutations.</p><p>This 12% figure can’t be understated. It projects to over 400,000 babies born with these mutations each year in the <a href="https://www.cdc.gov/nchs/fastats/births.htm">United States</a> alone, and over 15 million <a href="https://ourworldindata.org/grapher/number-of-births-per-year">globally</a>.</p><p>For families, these aren’t abstract percentages. They are stories of lives changed: A baby whose genetic result prompted a scan that found — and allowed monitoring of — a narrowing aorta. A child with biotinidase deficiency who has been spared brain damage by taking a daily supplement. A newborn whose <em>BRCA2</em> finding revealed his own mother’s cancer risk, leading her to preventive surgery that may have saved her life.</p><p>Each of these cases illustrates why sequencing is not simply about information — it’s about the opportunity to act before it’s too late.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/453/1*MKtiA_xiLiW2P71gcxi-iQ.png" /><figcaption><em>Three mothers whose infants were identified to have a genetic risk in BabySeq</em></figcaption></figure><p>While not every child (or adult) will end up actually experiencing these diseases, this information gives them advance notice, something to watch for, information to share with their doctors to make sure these uncommon conditions — with symptoms that otherwise could easily be overlooked or misdiagnosed — are on their radar. For many of these conditions, treatment isn’t available today, but it <em>will</em> be available in the future. This is how sequencing saves lives.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/448/1*6FAhvw_RrvKtD1zyNZtjtw.png" /><figcaption>In the U.S., standard newborn screening (bottom orange line) still trails far behind the projected number of treatable genetic conditions (top red line). (<a href="https://onlinelibrary.wiley.com/doi/10.1002/ajmg.c.31874">Source</a>)</figcaption></figure><h3><strong>A Bigger, Better Newborn Screening</strong></h3><p>The type of traditional newborn screening currently offered around the world has saved countless lives, but it hasn’t been able to keep up with the pace of genomic advances. In the U.S., each state screens for between 30–60 conditions, and since 2008, only nine new genetic conditions have been added to the standard newborn screening list.</p><p>The gap between what is possible and what is practiced keeps growing. If we want to close it, we need to bring genomics into newborn screening in a responsible and scalable way.</p><p>At TED, I explained why this isn’t just a local challenge — it’s a global one. This is why I envisioned and co-founded the International Consortium on Newborn Sequencing (ICoNS). ICoNS started as a small network and has now grown to 27 partners around the world, each exploring how to implement genomic sequencing for newborns within their own healthcare systems. We share results, compare strategies, and confront challenges together. Our May 2025 <a href="https://www.genomes2people.org/wp-content/uploads/2025/03/20250509_Minten_gene-list-comparison-for-gNBS-projects.pdf">paper in <em>Genetics in Medicine</em></a> compared gene lists across all 27 global programs, and created a ranked, adaptable gene list to guide more consistent and informed global practice. To me, ICoNS feels like the birth of a new field of medicine, one that requires global partnership to realize its potential.</p><p>And now, this vision is taking a bold new step forward. I am honored to serve as one of the multiple principal investigators on <a href="https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/beacons-first-us-national-genomic-newborn-screening-initiative">BEACONS</a>, a newly launched, NIH-funded multi-state collaboration that plans to enroll up to 30,000 newborns across the country to evaluate the feasibility of integrating genomic sequencing into the U.S. public health newborn screening system. This initiative, the first of its kind at a national scale, reflects how quickly the promise I spoke about on the TED stage is moving toward real-world implementation.</p><p>In my TED Talk, I shared why this work matters now more than ever, and why it will take courage — on the part of scientists, parents, healthcare systems, and policymakers — to move from treating illness to anticipating and preventing it. If we can embrace this shift, we won’t just save lives; we’ll redefine medicine itself.</p><p><a href="http://www.genomes2people.org/about/director/"><em>Robert C. Green, MD, MPH</em></a><em>, is a medical geneticist and physician-scientist who directs the </em><a href="https://www.genomes2people.org/"><em>G2P Research Program</em></a><em> in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School. Follow him at </em><a href="https://x.com/RobertCGreen"><em>@RobertCGreen</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e57fe3d54e6a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Life Saved by Expanded Newborn Screening]]></title>
            <link>https://genomes2people.medium.com/a-life-saved-by-newborn-sequencing-3eb6730df942?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/3eb6730df942</guid>
            <category><![CDATA[pediatric-neurologist]]></category>
            <category><![CDATA[spinal-muscular-atrophy]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[zolgensma]]></category>
            <category><![CDATA[prenatal]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Thu, 26 Sep 2024 17:33:46 GMT</pubDate>
            <atom:updated>2024-09-27T00:51:39.882Z</atom:updated>
            <content:encoded><![CDATA[<p><em>For a time-sensitive genetic disease, early detection is everything.</em></p><p>by Carolyn Philstrom, Independent SMA advocate*</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-7wSgyRRLbdzQUGe0l4P6w.png" /></figure><p>The news brought tears of joy to my eyes: Large-scale studies of genomic sequencing in newborns are <a href="https://www.washingtonpost.com/science/2024/06/17/sequence-baby-genome-diseases/?fbclid=IwY2xjawEPh2dleHRuA2FlbQIxMAABHfNzjFGQXSieVhK0rzsQ3NupU88HgEJXY388bmEWktCFhkUKIl9QQDAfhA_aem_mLvFlk-NuFn_0Q3SKlaW9g">finally getting underway</a>. As the mother of a child whose life was saved by newborn screening, I’ve been advocating and praying for this day for over five years.</p><p>My son Edan was one of the first humans ever to receive a Spinal Muscular Atrophy diagnosis from newborn screening, allowing treatment before the onset of symptoms. Those symptoms can begin very early, and can be extremely serious; SMA used to be the most common genetic cause of infant mortality, but in many parts of the world, that is changing thanks to newborn screening and new treatment options. Thanks to newborn screening and gene therapy, my son just started kindergarten with no signs of SMA.</p><p>When Edan was born in October 2018, Minnesota had recently become just the third state to screen for SMA in newborns. Edan was treated at two weeks old, eventually receiving the (then) new gene therapy Zolgensma. We traveled to a clinical trial site in Madison, Wisconsin, to receive the one-time treatment. Minnesota had newborn screening for SMA but no treatment for it; Wisconsin had the miracle drug but no screening. All over the country, babies were missing their chance for early treatment of SMA because of its omission from newborn screening panels. On that trip, my husband and I joined the group effort and odyssey, and I do mean odyssey, of getting all 50 states to screen for SMA. State by state. Just one disease, and it took years.</p><p>When we met with Wisconsin Governor Tony Evers, it was the only time I ever saw our pediatric neurologist show frustration as she described the terrible irony of having access to the treatment, but not the testing. As we say in the SMA community, time is motor neurons. And there are other genetic diseases even more acute and time-sensitive than SMA. When we did our <a href="https://www.bloomberg.com/news/articles/2019-07-17/newborn-screening-for-rare-disease-can-be-a-life-or-death-lottery">first</a> of <a href="https://www.washingtonpost.com/brandstudio/novartis/the-case-for-screening-every-newborn/">two</a> national news stories on this topic, one of the reporters cried when I explained that even though this miracle of gene therapy finally existed, some babies were not getting it in time.</p><p>When Edan was diagnosed, I read Dr. Siddhartha Mukherjee’s book <a href="https://siddharthamukherjee.com/the-gene-an-intimate-history/"><em>The Gene</em></a> and fell in love with genetics. I kept pondering how to improve the process of adding newly actionable diseases to state newborn screening panels. This made me wonder: “Why don’t we just sequence the genomes of all humans at birth and at least screen for all actionable diseases?”</p><p>I researched who was already working on this idea. Just days before, Dr. Robert Green of the <a href="https://www.genomes2people.org/">Genomes2People</a> (G2P) Research Program <a href="https://www.genomes2people.org/is-it-too-soon-to-consider-genome-sequencing-for-newborns/">had written an article on the topic</a>. I emailed him, figuring it was a long shot. He and his team met with me three times and helped me understand this idea. I never in my life thought I, a Lutheran pastor from Minnesota, would be talking with Harvard scientists. They helped me learn and advocate. Because God works through science, and because there is no such thing as other people’s children.</p><p>This is an issue that impacts us all. In the era of gene therapies, we must be able to get them to the babies in time. The reason we have COVID vaccines is because we were able to sequence the genome of the virus. We should apply this life-saving technology to humans, and upon birth is the ideal time to do it. It’s hard to state the scale and the importance of this work and what this will mean for human health. I am now a proud supporter of Dr. Green’s <a href="https://www.genomes2people.org/giving/">Genomes2People</a> project, and I encourage anyone interested in advancing this remarkable research to support the field in any way they can.</p><p>Gregor Mendel, clergy turned geneticist, famously said, “I am convinced that it will not be long before the whole world acknowledges the results of my work.” That day has finally arrived. Thanks be to God.</p><p><em>*Rev. Philstrom is not connected with Mass General Brigham or Harvard Medical School. All opinions are her own. She is an ordained minister in the Evangelical Lutheran Church in America (ELCA) and works as a healthcare chaplain.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3eb6730df942" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Second Revolution of Newborn Screening]]></title>
            <link>https://genomes2people.medium.com/the-second-revolution-of-newborn-screening-5dd63aebdd1a?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/5dd63aebdd1a</guid>
            <category><![CDATA[newborn-screening]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[pediatrics]]></category>
            <category><![CDATA[genome]]></category>
            <category><![CDATA[genetic-testing]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Wed, 10 Jul 2024 14:17:19 GMT</pubDate>
            <atom:updated>2024-07-10T17:09:44.916Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Newborn sequencing programs have a lot to learn about traditional Newborn Screening.</em></p><p>by <a href="https://www.linkedin.com/in/jos%C3%A9-manuel-gonz%C3%A1lez-de-aledo-castillo-5b7a0b83/">José Manuel González de Aledo Castillo</a>, PhD, Research Fellow, <a href="https://www.genomes2people.org/">Genomes2People</a></p><figure><img alt="Two hands in blue medical gloves take a blood sample from a newborn’s heel." src="https://cdn-images-1.medium.com/max/1024/1*5ZxI9vXExIV9skbXUib6Ng.jpeg" /></figure><p>Since its introduction in the early 1960s, newborn screening has saved thousands of lives. Probably millions.</p><p>Newborn screening (NBS) began with a bacterial inhibition assay, but has been continuously evolving, constantly adapting to the emerging technologies, and developing specific methodologies to improve its performance and extend its scope. The first revolution came with the development of tandem mass spectrometry, which allowed NBS programs to expand from a few diseases to around 50 additional disorders in a single test.</p><p>NBS programs have not only grown and changed technologically; the ethical considerations and patients’ perspective have changed over the years. <a href="https://medicalcriteria.com/web/epiwj/">Wilson and Jungner criteria</a> provided a stable guideline that professionals of NSB can rely on when considering expanding NBS programs. Patients’ access to a broader health knowledge, along with a more defined ethical framework regarding consent and confidentiality, have made NBS programs more democratic in terms of decision-making. However, policymakers have not evolved in the same way. On the contrary, bureaucracy has slowed down attempts to expand NBS programs in many countries, making it difficult to achieve an equitable access; meanwhile, in countries with a low human development index, NBS often isn’t present at all.</p><p>The second revolution of NBS programs is about to come. In the last 20 years, genetic sequencing technology, genetics and genomics have rapidly evolved. Next-generation sequencing has substantially reduced sequencing costs while increasing quality and quantity of results. Our knowledge of gene-disease association keeps expanding, along with related sciences such as bioinformatics, all making whole genome sequencing more and more useful in clinical settings.</p><p>These developments have affected NBS programs, which have gradually incorporated whole exome and/or genome sequencing in their algorithms to reach the final diagnosis of affected children. Pilot programs in the U.S., Europe and Australia have started exploring the inclusion of genome or exome sequencing in NBS programs not only for diagnosing affected children, but for the whole newborn population. Now the first results of these pilot programs are becoming public, allowing us to better understand the challenges and possibilities of genomic NBS programs. One such challenge is the lack of consensus on how and when to obtain consent for genomic testing — and, critically, on which genes should be included in this testing. Concerns about confidentiality, data storage and re-use are also important issues that need to be addressed in the near future.</p><p>Genomic newborn screening is here to stay, and traditional NBS is not going anywhere. The question is: How do we integrate both? Or should they be integrated at all? Are both approaches complementary, independent, or exclusive? My own opinion, after a few years of experience in traditional NBS and after a first approach to newborn sequencing through the <a href="https://www.genomes2people.org/research/babyseq/">BabySeq project</a> in Boston, is that they should be complementary.</p><p>I also think that newborn sequencing has a lot to learn about traditional NBS. Traditional NBS programs have well-established circuits of dried blood spots extraction, transport of those samples to the laboratory, sample reception, and temporary and permanent storage. They also have Laboratory Information Systems collecting all the clinical and demographic data of the newborns. They have built robust relationships with neonatology departments and midwife networks over the years. Professionals of traditional NBS are used to working with both families and providers; they know how to handle the complexity of NBS from every angle. Newborn sequencing programs should take advantage of all of this, join forces with traditional NBS programs and work together.</p><p>The ideal scenario would be a NBS program with only one preanalytical and administrative area; one Laboratory Information System with modules for both traditional NBS and genomic sequencing results; and two laboratories, one for traditional methodologies and one for the genomic analysis. Professionals in these two areas should work closely together, sharing relevant information for every case. Traditional NBS results will be available sooner, but in my experience some doubtful cases can be resolved only through genomic analysis. On the other hand, doubtful genomic results, such as variants of unknown significance, might be resolved with biochemical tests, especially in the metabolic diseases area, as metabolomic approaches seem to be the next revolution for traditional NBS. The combination of both approaches will help improve genomic knowledge and will help to detect cases where there is a genomic alteration, but the biochemistry is not altered yet. With the inclusion of newborn sequencing the NBS programs will expand the range of conditions to be screened, and the improvement in knowledge will allow the inclusion of new conditions easily and at a low cost.</p><p>Once newborn sequencing has overcome the unresolved questions mentioned above, policymakers, health professionals, laboratory specialists and patients should advocate for a merger between traditional NBS and genomic sequencing in newborns in one single NBS program. This must be done while maintaining the equity values that have guided NBS for more than 50 years; newborn sequencing should be universally available. If we do all of this, we will reduce costs, expand the scope of NBS, and improve newborns’ care and future.</p><p><em>You can reach the author at </em><a href="/service/mailto: jgonzalezdealedocastillo@bwh.harvard.edu">jgonzalezdealedocastillo@bwh.harvard.edu</a> <em>or at</em> <a href="/service/mailto:gonzalezde@clinic.cat">gonzalezde@clinic.cat</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5dd63aebdd1a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Tribute to Franca Sozzani: Celebrating FiveYears of the Franca Sozzani Fund for Preventive…]]></title>
            <link>https://genomes2people.medium.com/a-tribute-to-franca-sozzani-celebrating-fiveyears-of-the-franca-sozzani-fund-for-preventive-bba439266e38?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/bba439266e38</guid>
            <category><![CDATA[philanthropy]]></category>
            <category><![CDATA[franca-sozzani]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[fashion]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Fri, 15 Mar 2024 15:32:16 GMT</pubDate>
            <atom:updated>2024-03-15T15:51:23.434Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>A Tribute to Franca Sozzani: Celebrating FiveYears of the Franca Sozzani Fund for Preventive Genomics</strong></h3><p>by Pakhi Rajesh Kumar Dixit</p><figure><img alt="A black-and-white photograph of Franca Sozzani, with white script: “Giving back is the new luxury. —  Franca Sozzani”" src="https://cdn-images-1.medium.com/max/1024/1*p0xalXRtMtbrTDn4i9hxmA.png" /></figure><p><strong>Franca Sozzani — A Trailblazer</strong></p><p>When it comes to fashion and philanthropy, few people carry the weight and stature of Franca Sozzani. An indomitable force in the fashion industry, Sozzani’s legacy extends far beyond the glossy pages of <em>Vogue Italia</em>, where she served as its iconic editor-in-chief for nearly three decades. Her passionate commitment to creativity, diversity, and social causes has left a lasting mark in the history of fashion journalism.</p><p>As an indelible testament to her groundbreaking spirit, one of the most notable issues she curated during her tenure was the “Black Issue” of <em>Vogue Italia</em> in July 2008, a bold and iconic edition that aimed to address the lack of diversity in the fashion world. Sozzani was driven to challenge and confront the industry and push for more inclusivity. This issue featured a stunning array of Black supermodels, unprecedented for a high-fashion magazine at the time, and catalyzed a transformative shift in fashion and media for the better.</p><p><strong>The Birth of a Visionary Initiative: Where Fashion Meets Science</strong></p><p>When Franca Sozzani was diagnosed with a rare form of lung cancer, her son Francesco Carrozzini, a photographer and filmmaker, reached out to Dr. Robert Green, a physician-scientist, Professor of Medicine at Harvard Medical School, and Director of the <a href="https://www.genomes2people.org/">Genomes2People</a> Research Program. Given that Dr. Green directs the <a href="https://www.brighamandwomens.org/medicine/genetics/genetics-and-genomic-medicine/preventive-genomics-clinic">first preventive genomics clinic</a> in the U.S., Carrozzini hoped something could be done to save his mother’s life. Tragically, by the time of the consultation, it was too late, and the world mourned the loss of this remarkable woman on December 22, 2016.</p><p>His mother’s passing, and his ongoing conversations with Dr. Green about preventive genomics and its potential to save and extend lives, inspired Carrozzini to embody his mother’s innovative spirit and relentless pursuit of challenging status quo, transcending boundaries, and initiating dialogues, but this time between fashion and science. With a strong commitment to honor his mother’s memory in a way that would raise awareness about the life-saving potential of preventive genomics, Francesco and Dr. Green, in collaboration with recording artist and investor D.A. Wallach, established the <a href="https://www.thefrancafund.org/">Franca Sozzani Fund for Preventive Genomics</a> in 2018 at Brigham and Women’s Hospital and Harvard Medical School.</p><p>In the words of Carrozzini, “<strong>There is much more in common between a fashion editor and genomics than people think</strong>.” The Fund supports <a href="https://www.genomes2people.org/">Genomes2People </a>(G2P), the scientific initiative driving these efforts. The aim: To save as many lives as possible through the power of preventive genomics, make precision medicine a reality, and bring fashion and science together for a noble cause.</p><p>As we celebrate the Fund’s remarkable five-year journey, we must recognize how Sozzani’s vision continues to shape the landscape of preventive genomics and its impact on healthcare. In Franca’s own words, “Fashion isn’t really about clothes; it’s about life.” While fashion represents the beauty of human creativity, genomics holds the key to understanding life’s core intricacies. By deciphering our genetic blueprint, preventive genomics empowers us to foresee and thwart potential health threats before they manifest. This proactive approach saves lives and reduces healthcare burdens, fostering a healthier, more resilient society and delivering precision health to everyone.</p><p><strong>The Science Behind The Fund</strong></p><p>Through various fundraising campaigns, events, and philanthropic exhibitions, the Fund provides vital economic support to the <a href="https://www.genomes2people.org/">G2P Research Program</a>.Through rigorous scientific research, we are establishing a foundation of evidence for genomic medicine that will accelerate the adoption of novel genomics-based technologies such as newborn genomic sequencing, model new approaches to care, and explore ways for patients, physicians, and consumers to use genomic information to achieve improved health and longevity.</p><p>“<strong>The ultimate benefits of genomic sequencing are no less than the transformation of medicine itself</strong> <strong>from a reactive enterprise of treating patients who are already ill to a proactive enterprise of preventing illness before it occurs</strong>,” emphasizes Dr. Green.</p><p>“<strong>There’s very few of us who go to the doctor because they’re healthy and want to stay healthy</strong>,” Carrozzini adds. “<strong>I speak out of experience, and I say, go to the doctors, in general, not only for [genetic] sequencing, just to get checked constantly because it might save your life.</strong>”</p><p>At its core, this Fund also embodies a commitment to social justice, aiming to create an equitable landscape in the future of medicine. Franca Sozzani’s legacy advocating for a better world is in the Fund’s DNA: to advance scientific knowledge through awareness, including a platform where patients can share their experiences with genetic sequencing, so that the benefits of this progress are accessible to all.</p><p><strong>Driving Awareness and Advocacy: Fashion for Good</strong></p><p>Franca Sozzani, an ambassador for <a href="http://www.fashion4development.com/">Fashion4Development </a>(F4D), believed in fashion’s potential for positive change. Last September, F4D hosted its 3rd Annual Sustainable Goals Banquet in NYC, focusing on “Healthier People, Healthier Planet.” Speakers included Italian supermodel Bianca Balti and Dr. Robert Green, who advocated for preventive genomics through genetic screening for informed health choices.</p><p>Balti shared her experience with preventive genomics at the event, revealing her BRCA1 gene discovery and subsequent double mastectomy. Her story encouraged others, especially women, to prioritize their health. Francesco Carrozzini emphasized the need for accessible genetic screening programs. Dr. Green further highlighted research suggesting 15% of the audience may have risky DNA mutations, urging a shift from fear to opportunity through genetic testing. The event honored Franca Sozzani’s legacy, recognizing the work of Carrozzini and Dr. Green in promoting evidence-based preventive genomics for all.</p><p><strong>This Is Just The Beginning!</strong></p><p>Franca Sozzani once said, “<strong>Giving back is the new luxury</strong>.” This quote is our North Star, reminding us daily that the Fund is about enhancing lives. As we celebrate the fifth anniversary of the Franca Sozzani Fund for Preventive Genomics, we see this as just the beginning. Endless possibilities lie ahead: more research and innovative discoveries, lives awaiting positive impact, and a legacy inspiring generations.</p><p>Franca Sozzani’s principle of always paying it forward is at the core of our remarkable work, and what better way than to save lives? As we celebrate this milestone, we honor her memory and reaffirm our commitment to a future where preventive healthcare knows no barriers; a world where healthcare is not just a privilege but a right for all.</p><p>Cheers to the future of healthcare; to the future of equitable medicine!</p><p><em>Pakhi Dixit handles social media for </em><a href="https://www.genomes2people.org/"><em>Genomes2People</em></a><em>, </em><a href="https://www.thefrancafund.org/"><em>The Franca Sozzani Fund for Preventive Genomics</em></a><em>, and the </em><a href="https://www.iconseq.org/"><em>International Consortium on Newborn Sequencing (ICoNS)</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bba439266e38" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Genomics Could Save Your Life]]></title>
            <link>https://genomes2people.medium.com/how-genomics-could-save-your-life-95e10cbefaee?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/95e10cbefaee</guid>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[genetics]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Mon, 12 Feb 2024 20:03:03 GMT</pubDate>
            <atom:updated>2024-02-12T20:03:03.393Z</atom:updated>
            <content:encoded><![CDATA[<p><em>What’s holding us back from doing more with preventive genomics in medicine?</em></p><figure><img alt="Dr. Robert C. Green stands at a podium in front of a screen displaying a title slide: “The Path to Universal Genomic Medicine.”" src="https://cdn-images-1.medium.com/max/1024/1*ON1UuTnQ5U1MUR8LsHzjZA.jpeg" /></figure><p>By Robert C. Green</p><p><em>Adapted from </em><a href="https://www.youtube.com/watch?v=rgdnkBngGp8"><em>my keynote</em></a><em> at the</em><a href="https://pmnetforum.com/"><em> Precision Medicine Network (PMNET) Forum</em></a><em> in Riga, Latvia.</em></p><p>I’d like more people to ask themselves: Why is the healthcare system not using genomics in my everyday healthcare?</p><p>We could all of us, right now, understand what’s in our genome. For some of us, it could be lifesaving.</p><p>Precision medicine covers everything from<a href="https://www.beckershospitalreview.com/digital-health/samsung-mass-general-brigham-partner-on-digital-health.html"> smart watches</a> to<a href="https://otd.harvard.edu/explore-innovation/technologies/liquid-biopsy-based-predictive-platform-for-early-cancer-detection-and-drug/"> liquid biopsies</a>, but genomics is the tip of the spear. Near-term applications are already here: diagnosis of rare conditions, some limited pre-conception carrier screening and embryo selection for hopeful parents, and various uses in cancer diagnosis and treatment. But I am most excited about the next phase of potential for genetic testing: newborn and childhood sequencing, expanded carrier screening for expecting parents, polygenic risk scores, new pharmacogenomics applications, and population screening for all age groups.</p><p>So why is preventive genomics not already used for these things?</p><p>There are reasonable concerns about privacy and discrimination if genetic information is misused or falls into the wrong hands, and worries that people (both patients and healthcare providers) won’t understand the information and will take harmful action as a result. We worry, in short, that preventive genomics could cause more <a href="https://genomes2people.medium.com/genome-sequencing-for-healthy-people-will-it-be-harmful-d915cc08e634">harm</a> than<a href="https://genomes2people.medium.com/genome-sequencing-for-healthy-people-will-it-be-helpful-b984b94e3d3f"> benefit</a>. Much of our own research has asked: What are the medical, behavioral, and economic outcomes associated with unanticipated findings from genomic sequencing?</p><p>We studied this over a decade ago with<a href="https://www.genomes2people.org/research/medseq/"> MedSeq</a>, the first randomized trial of comprehensive genome sequencing in apparently healthy people. In this study, we gave genomic sequencing data to participants through their primary care physicians and followed up to see how they — and their doctors, who we trained to read the results — responded to this information about themselves. In the process, we made a startling discovery. We found that 20% of apparently healthy adults were carrying a monogenic disease risk. This doesn’t mean you <em>have</em> the disease, but it does mean that you have a significant risk of expressing the disease at some point in your life.</p><p>Even more interestingly: Those 20% of participants reported no significant difference in anxiety after receiving their results compared to the other 80% of participants. The doctors weren’t overwhelmed with the genomic reports, and they relayed accurate information to the patients with very few errors. We even tracked downstream medical referrals and follow-up testing and found that participants’ healthcare spending didn’t go through the roof in response. In short, the benefits outweighed the harms.</p><p>With <a href="https://www.genomes2people.org/research/babyseq/">BabySeq</a>, we did something similar with newborn and infant screening, vastly expanding the standard screening experience with whole exome sequencing and interpretation of approximately 1,000 genes. We found unanticipated and potentially important mutations in 11% of newborns who had not previously been suspected of having genetic diseases. These results allowed parents and providers to look more closely for clinical indications of those specific conditions, and in many cases to take preventative actions that could have enormous benefit for the rest of the child’s life. And once again, <a href="https://www.genomes2people.org/wp-content/uploads/2021/08/20210823_BabySeq_Pereira_JAMApediatrics_PsychosocialEffectNGSonFamilies.pdf">we found</a> that a few months later, parents of those 11% of newborns with clinically important mutations weren’t any more anxious or distressed than the other 89% of parents in the study.</p><p>There’s another way we can save lives in the very near term: We can <a href="https://genomes2people.medium.com/how-genomic-researchers-can-save-their-participants-lives-5d49a966099e">return incidental genomic results</a> to research participants who undergo any form of genetic testing. About 100 million people in the world have been sequenced for research, and across the surveys of those participants, 70–80% said that they wanted their genetic results returned to them. Yet this is almost never done, due to a combination of concerns about logistics and participants’ “right not to know” — and perhaps because it is more work and more expense for the researchers, requiring <a href="https://genomes2people.medium.com/how-frequently-should-genomic-results-be-updated-548cf2fcc9b8">thoughtful design</a> at the front end of the study. Indeed, in 2021, we coordinated a <a href="https://www.genomes2people.org/wp-content/uploads/2021/07/20210715_GenomeMedicine_Lewis_internationalpolicygRoR.pdf">recommendation paper</a> from the Global Alliance for Genomic Health that recommended strong consideration of returning incidental or secondary findings in every research project that utilizes genetic testing!</p><p>Again and again, people tell us that they want this information. One BabySeq parent told us, after learning through the study that her son had a genetic heart condition: “I feel more empowered to have the information . . . If we know more, we can do the best for our kids.” Another parent said: “Knowing any additional information is going to be helpful down the road.” And across the board, parents said that if given the opportunity, they would do it again. You can hear this directly from the powerful voices of <a href="https://youtu.be/5ki_XTfN7jc">parents who have screened their children through BabySeq</a>.</p><p>I believe we should treat genomic information more like we treat other medical information, sharing it more often with individuals and trusting them, and their healthcare providers, to be able to handle it. We could be focusing on helping people to understand their genomic sequencing data, rather than shielding them from it.</p><p>If we’re going to respect the autonomy of patients and participants, we need to ask them if this is something they want. If they do want it — and many, if not most of them, will want it — then we need to be prepared to deliver it to them.</p><p><a href="http://www.genomes2people.org/director/">Robert C. Green</a>,<em> M.D., M.P.H., is</em> <em>a medical geneticist and physician-scientist who directs the </em><a href="http://www.genomes2people.org/g2p/">G2P Research Program</a><em> in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=95e10cbefaee" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Global Leaders Convene in London: Advancing Newborn Sequencing on an International Scale]]></title>
            <link>https://genomes2people.medium.com/global-leaders-convene-in-london-advancing-newborn-sequencing-on-an-international-scale-590c8af350d7?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/590c8af350d7</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[medical-conferences]]></category>
            <category><![CDATA[neonatal-care]]></category>
            <category><![CDATA[genetic-testing]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Tue, 17 Oct 2023 18:46:38 GMT</pubDate>
            <atom:updated>2023-10-18T01:38:34.795Z</atom:updated>
            <content:encoded><![CDATA[<p><em>The second International Conference on Newborn Sequencing (ICoNS) brings together leading researchers in newborn sequencing.</em></p><p>by Rose Heald &amp; Nic Encina</p><figure><img alt="A group photo of attendees of the second International Conference on Newborn Sequencing, in a large auditorium" src="https://cdn-images-1.medium.com/max/1024/1*SF1C7pAoYnNIAraaW1OUfQ.jpeg" /><figcaption>Photo credit: ICoNS</figcaption></figure><p><em>“Over the course of the next few decades, the availability of cheap, efficient DNA sequencing technology will lead to a medical landscape in which each baby’s genome is sequenced, and that information is used to shape a lifetime of personalized strategies for disease prevention, detection, and treatment.”</em></p><p><em>— </em><a href="https://www.wsj.com/articles/francis-collins-says-medicine-in-the-future-will-be-tailored-to-your-genes-1404763139"><em>Francis S. Collins, 2014</em></a></p><p>The sequencing of the first human genome was completed with the <a href="https://www.genome.gov/human-genome-project">The Human Genome Project</a> in 2003. Now, twenty years later, conversations about the widespread genome sequencing of newborn babies are happening all over the world. Newborn genome sequencing has the potential to <a href="https://genomes2people.medium.com/newborn-genome-sequencing-the-next-step-in-public-health-56f9a8e79042">completely transform newborn screening</a> and health care as we know it. So: Are we ready?</p><p>In 2015, Phase I of <a href="https://www.genomes2people.org/research/babyseq/">The BabySeq Project</a> was a first-of-its-kind randomized clinical trial designed to assess the use of genomic sequencing in routine newborn care. Since then, research on newborn sequencing has accelerated as more programs are taking on the question of how to make newborn sequencing a public health reality. In order to maximize efficiency and progress in this space, we’ll need to prioritize collaboration and sharing among leaders and investigators. It was from this idea that the <a href="https://www.iconseq.org/">International Consortium on Newborn Sequencing (ICoNS)</a> was born.</p><p>Earlier this month, leading researchers and experts in genomics and newborn sequencing representing the U.S., the U.K., Europe, Australia, and the Middle East came together in London at the Royal Institution for the second annual <a href="https://www.iconseq.org/home-1-1">International Conference on Newborn Sequencing</a> co-hosted with Genomics England to <a href="https://www.genomeweb.com/molecular-diagnostics/international-newborn-genome-sequencing-projects-discuss-differences-future">present updates regarding their own research and share future plans</a>.</p><p>The annual conference is put on by the International Consortium on Newborn Sequencing, which was founded in 2022 by the leaders of eight newborn sequencing research projects (<a href="https://www.genomes2people.org/research/babyseq/#:~:text=The%20BabySeq%20project%20revealed%20unanticipated,conditions%2C%20allowing%20for%20personalized%20management.">BabySeq</a>, <a href="https://www.genomicsengland.co.uk/">Genomics England</a>, <a href="https://guardian-study.org/">GUARDIAN Study</a>, <a href="https://radygenomics.org/begin-ngs-newborn-sequencing/">BeginNGS</a>, <a href="https://earlycheck.org/what-is-early-check/who-we-are/">Early Check</a>, <a href="https://screen4care.eu/">Screen4Care</a>, <a href="https://www.einsteinmed.edu/research/screenplus/">ScreenPlus</a>, and <a href="https://www.melbournegenomics.org.au/about-us/our-work/project-portfolio/implementation/baby-beyond-hearing-study-additional-screening-genome-infants">BabyBeyond</a>) as a global alliance of stakeholders in this space. The Consortium has been intentional in seeking perspectives from and collaboration amongst scientists, government officials, industry leaders, healthcare providers, ethicists, and patient advocates who share a common vision of implementing newborn sequencing in public health.</p><p>Nicolas Encina, co-founder and Executive Director of ICoNS, explains that “robust and effective clinical implementation of newborn sequencing can only be achieved through common understanding and coordination across the critical stakeholders that are required to build the infrastructure necessary to support it at population levels.”</p><figure><img alt="Dr. Robert C. Green stands, hands raised in a gesture, at a white podium bearing the ICoNS logo." src="https://cdn-images-1.medium.com/max/1024/1*k_hoR0vF2NGRZUNaLKKNYQ.jpeg" /><figcaption>Robert Green shares updates on the BabySeq Project at ICoNS’23. Photo credit: ICoNS</figcaption></figure><p>Since its debut in 2022, the Consortium has doubled in size and now includes <a href="https://www.iconseq.org/the-consortium">17 newborn sequencing projects</a> from seven countries around the globe. This year, the conference included presentations from 12 international newborn sequencing research projects (<a href="https://www.genomicsengland.co.uk/initiatives/newborns">Generation Study</a>, <a href="https://earlycheck.org/">EarlyCheck</a>, <a href="https://screen4care.eu/">Screen4Care</a>, <a href="https://www.genomes2people.org/research/babyseq/">BabySeq</a>, <a href="https://www.einsteinmed.edu/research/screenplus/">ScreenPlus</a>, <a href="https://babyscreen.mcri.edu.au/">BabyScreen+</a>, <a href="https://guardian-study.org/">GUARDIAN</a>, <a href="https://www.qf.org.qa/research/precision-health">Qatar Pediatric Precision Medicine Program</a>, <a href="https://radygenomics.org/begin-ngs-newborn-sequencing/">BeginNGS</a>, PERIGENOMED, <a href="https://www.sapathology.sa.gov.au/wps/wcm/connect/sa+pathology+internet+content+new/content/news/world-first+research+to+help+newborn+babies">NewbornsInSA</a>, and FirstSteps) complemented by panel discussions and additional sessions focused on critical issues in the newborn sequencing space, such as upstream tools and services and downstream support systems necessary for implementation, economic considerations, care delivery, health policy, patient perspectives, ethics, and data sharing.</p><p>In addition to being a platform for experts to discuss relevant issues in newborn sequencing, the conference also presented an opportunity for the Consortium to identify key priorities based on input from conferees. In a poll facilitated by Dr. Aaron Goldenberg, conferees identified having a space for idea exchange and harmonizing outcome measures as two of the most valuable ways that ICoNS can support consortium members.</p><p>An explicit objective of ICoNS is to harmonize evidence and address precompetitive industry challenges that benefit all participants. In that spirit, an ICoNS working group has been establishing a mechanism for making project documents and materials available to new projects, aligning on terminology and metrics, and ultimately consolidating results data such that researchers may learn in aggregate, thereby propelling the field forward as a whole at a more rapid pace. At the 2023 meeting, Dr. David Bick, Dr. Nidhi Shah, and Rose Heald unveiled an ICoNS Member Network to facilitate easy communication and future data sharing within the consortium, which organizations and individuals may <a href="https://members.iconseq.org/">request to join here</a> for free.</p><p>The Consortium is co-chaired by Drs. Robert Green (BabySeq) and David Bick (Genomics England). “We felt that creating a centralized place for collaboration and knowledge sharing is essential for driving research and innovation in this space,” said Robert Green, Director of Genomes2People. “ICoNS provides an excellent opportunity for global leaders in newborn sequencing to come together with the shared vision of preventing treatable disease before it even begins.”</p><p>Next year, <a href="http://www.icons24.org/">ICoNS will be held in New York City on October 9–10, 2024</a> (<a href="http://www.icons24.org/">www.icons24.org</a>). We hope to see you there!</p><p><a href="http://www.linkedin.com/in/rose-heald-555505219"><em>Rose Heald</em></a><em> is a Research Assistant with the Genomes2People Research Program at Brigham and Women’s Hospital and Harvard Medical School.</em></p><p><a href="https://www.linkedin.com/in/encina/"><em>Nic Encina</em></a><em> is Executive Director of the International Consortium on Newborn Sequencing (ICoNS) and Director of Strategy of the Precision Population Health Initiative at Ariadne Labs and Harvard T.H. Chan School of Public Health.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=590c8af350d7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Precision Screening for Health Equity]]></title>
            <link>https://genomes2people.medium.com/precision-screening-for-health-equity-b8d5f197f243?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/b8d5f197f243</guid>
            <category><![CDATA[racial-equity]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[cancer-screening]]></category>
            <category><![CDATA[precision-medicine]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Wed, 21 Jun 2023 12:57:11 GMT</pubDate>
            <atom:updated>2023-06-21T12:57:11.444Z</atom:updated>
            <content:encoded><![CDATA[<p>by Morgan Danowski and Jason Vassy</p><figure><img alt="Wallpaper-style graphic depicting rows of figures in silhouette, wearing suits and ties and porkpie hats, identical except for color" src="https://cdn-images-1.medium.com/max/1000/1*MD-VbMKLePjvwkiMqQSBhw.png" /></figure><p><em>A new paradigm of precision prostate cancer screening could increase benefits and lower harms.</em></p><p>The most common cancer among men in the United States, besides skin cancer, is prostate cancer. Black men in the U.S. are 60% more likely to be diagnosed with prostate cancer than white men — and <a href="https://seer.cancer.gov/statfacts/html/prost.html">twice as likely</a> to die from it. Even in a world with<a href="https://medium.com/@genomes2people/making-genomics-as-diverse-as-humanity-87bdfe42ca72"> </a>significant racial disparities in health, these statistics are particularly striking. The gap isn’t easily explained by a single factor. The disparities — and prostate cancer risks in general — are likely due to <a href="https://pubmed.ncbi.nlm.nih.gov/35040965/">both environmental and genetic</a> factors.</p><p>We could reduce prostate cancer metastasis and death for all men by catching it earlier, but the lack of an optimal screening strategy to identify men at high risk is a major barrier. And it’s not as easy to address as you might think.</p><p>Many guidelines do not recommend prostate cancer screening for the average man, because the potential risks of screening (unnecessary biopsies and treatment) may not outweigh the benefits. One <a href="https://pubmed.ncbi.nlm.nih.gov/29801017/">important set of guidelines</a> identifies family history and race as risk factors but does not specify different screening recommendations for these populations, while<a href="https://www.nccn.org/guidelines/category_1"> another set of guidelines</a> nudges toward screening higher-risk patients starting at age 40.</p><p>A new paradigm of precision screening could be the answer. Tailoring screening strategies to an individual’s genetic profile can save lives while reducing harm and clearing up confusion about whether or not to screen. It could also replace the problematic use of race — a social construct with no actual biological meaning — as a means of assessing patient risk.</p><p><a href="https://www.genomes2people.org/publications/development-of-clinical-polygenic-risk-score-assay-and-report/">Polygenic risk scores</a> (PRS) are an important element of this strategy. These combine many genetic markers, from dozens to millions, to categorize men as either low- or high-risk for prostate cancer. A high PRS can be considered its own risk factor, independent from traditional risk factors such as family history and race. But if physicians have been using race as a primary indicator of prostate cancer risk for years, will they be receptive to PRS as a new risk assessment?</p><p>We <a href="https://www.genomes2people.org/publications/primary-care-physician-use-of-patient-race-and-polygenic-risk-scores-in-medical-decision-making/">decided to investigate</a> this question. We used clinical vignettes to survey a national sample of 369 primary care physicians (PCPs) on their perceived utility of a PRS to inform prostate cancer screening recommendations. Compared against patients with no PRS results, PCPs were significantly less likely to recommend screening to patients with low-risk PRS results and more likely to recommend it to those with high-risk PRS results. These hypothetical results suggest PCPs’ willingness to consider PRS results in screening recommendations. However, PCPs were still almost twice as likely to recommend screening to a Black patient compared with an otherwise identical white patient, regardless of PRS results. There are many important questions remaining to disentangle how physicians and patients will use the social construct of race and the biological construct of genetic make-up in decision-making. It is critical to get these questions right, given the profound health disparities.</p><p>Now we’re planning to enroll a diverse group of men to participate in a pragmatic randomized clinical trial comparing this type of DNA-based precision screening for prostate cancer risk to the current standard of care. The performance of PRS in diverse ancestry groups is improving, but concern remains that underrepresented populations will distrust the use of genetic screening in healthcare decision-making. This project will tackle these challenges directly by recruiting a racially diverse cohort of screen-eligible men to receive a state-of-the-science PRS while transparently framing the limitations of the results. The trial’s pragmatic design will allow participants to make individual decisions about screening, which might differ from the recommendations provided in the intervention.</p><p>Addressing stark, deeply-rooted racial disparities in healthcare has to be a priority for medical research. PRS might be one tool to improve disease screening and move us beyond race-based medical decision-making and toward more equitable health outcomes.</p><p><em>Morgan Danowski is a genetic counselor with the </em><a href="https://www.genomes2people.org/research/genomes2veterans/"><em>Genomes2Veterans Research Program</em></a><em> returning actionable genetic testing results to veterans nationwide.</em></p><p><em>Jason Vassy directs the </em><a href="https://www.genomes2people.org/research/genomes2veterans/"><em>Genomes2Veterans Research Program</em></a><em> and is an Associate Professor of Medicine at Harvard Medical School. He practices primary care at the </em><a href="https://www.va.gov/boston-health-care/"><em>VA Boston Healthcare System</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b8d5f197f243" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Is it Time for Health Systems to Offer Preventive Genomic Screening?]]></title>
            <link>https://genomes2people.medium.com/is-it-time-for-health-systems-to-offer-preventive-genomic-screening-59b52daa8a26?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/59b52daa8a26</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[prevention]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Fri, 31 Mar 2023 18:50:16 GMT</pubDate>
            <atom:updated>2023-03-31T18:50:16.258Z</atom:updated>
            <content:encoded><![CDATA[<p><em>We know this screening saves lives. Why aren’t health systems adopting it?</em></p><figure><img alt="A man in a lab coat climbs up a silver DNA helix, using a red ladder." src="https://cdn-images-1.medium.com/max/706/1*mp8tDlweHqF4iL55F0aXmw.png" /></figure><p>By Carrie Blout Zawatsky</p><p>Preventive genomic screening (aka elective testing) has been offered in research settings and directly to consumers for nearly a decade. Direct to consumer (DTC) testing has reached over 100 million <a href="https://www.ama-assn.org/delivering-care/patient-support-advocacy/protect-sensitive-individual-data-risk-dtc-genetic-tests">individuals</a>. Large research initiatives such as health system biobanks and NIH’s <a href="https://allofus.nih.gov/"><em>All of Us</em> Research Program</a> are offering preventive genetic testing results (unrelated to a medical indication) to millions of people. And some cutting-edge health centers are starting to offer preventive genomic screening clinically to their patients.</p><p><a href="https://www.brighamandwomens.org/medicine/genetics/genetics-and-genomic-medicine/preventive-genomics-clinic">The Preventive Genomics Clinic</a> at Brigham and Women’s Hospital launched in 2019, and was the first academically affiliated clinic to provide preventive genomic screening to healthy adults who are seeking to understand and mitigate their risk of genetic disease in themselves and their family members.</p><p>At this point, we can safely say that genomic screening can identify genetic risk factors that have direct medical screening and management implications. There is even preliminary evidence that for some of the most common conditions, like Hereditary Breast and Ovarian Cancer, preventive screening may be cost effective–on top of saving lives.</p><p>Professional genetics organizations have developed consensus documents surrounding this topic; the National Society of Genetic Counselors just published a <a href="https://www.genomes2people.org/wp-content/uploads/2023/01/20230104_JOGC_Zawatsky_ElectiveGenomicTestingPracticeResourceNSGC.pdf">practice resource</a> on elective genetic testing and the American College of Medical Genetics and Genomics (ACMG) has also published <a href="https://pubmed.ncbi.nlm.nih.gov/33790423/">multiple</a> <a href="https://pubmed.ncbi.nlm.nih.gov/33727704/">documents</a> on this topic. In fact the ACMG set the stage for this in 2013 when they published a list of genes that they deemed to have enough medical actionability to be returned if found incidentally (unexpectedly) when testing for other genetic conditions. Though not its intended purpose, this list, which has been updated four times since, is often used or adapted by health centers when offering this type of screening on a research or clinical basis to their patients.</p><p>So what is holding health systems back from offering this type of testing clinically? Admittedly, there is still clinical utility data being collected to better understand all the implications and, yes, there is still the question of balancing sacred health care resources in a climate prone to health care provider burnout and overspending. But is there something more to the holdup? As with any new(ish) technology, especially a genetic technology, health insurers are waiting to have more comprehensive clinical utility data before providing coverage. But is this a big enough reason to restrict offering this potentially life saving technology to patients who want it? Especially when research studies <a href="https://www.genomes2people.org/wp-content/uploads/2018/07/20170627_MedSeq_AnnalsInternalMedicine_Vassy_WGSPrimaryCare.pdf">are showing</a> <a href="https://www.genomes2people.org/wp-content/uploads/2021/08/20210823_BabySeq_Pereira_JAMApediatrics_PsychosocialEffectNGSonFamilies.pdf">no increases</a> in negative health outcomes, like increased patient anxiety/depression or medical mismanagement?</p><p>Is genomic screening cost prohibitive? Maybe, but some might argue that for a few hundred dollars, cost is becoming less of an issue (the first BRCA single gene testing was over $3,000). In fact we know that many individuals typically underrepresented in medical research are very interested in this type of testing, and that the labs that give them access to genetic screening, either via a DTC test or a physician mediated test (ordered by a physician connected to the lab), are actually increasing their access because they just are not getting it through their medical providers. Other groups at medical risk, like those who are adopted, have no other option to learn this health information, and many don’t know how to get it other than ordering DTC testing, which offers limited health information due to stricter FDA regulations. Patients don’t even realize that they could be getting a more medically informative test if it was ordered by their healthcare provider.</p><p>Though all of these components are part of the big picture in explaining why population based preventive genomic testing is not clinically available at the health system level, we argue that the real reason it is not available is due to implementation challenges. Health systems can see the potential in this type of testing, but aside from getting millions of dollars in grants to help pay for the infrastructure to offer the test, they just don’t see a path forward. Implementation of healthcare innovations can be considered the “last mile” in getting new technologies in the hands of clinicians, but the devil is in the details, and this last mile often proves to be the hardest in launching emerging forms of care. And when you consider the breadth of changes required to prepare a health system to offer genetic screening, these changes often become a huge barrier to entry.</p><p>But what if a simple scalable path forward could be designed to make preventive genomic testing a reality, one that considers the needs of the patients, the providers and the leadership? That is exactly what the <a href="https://www.ariadnelabs.org/precision-population-health/">Precision Population Health</a> (PPH) initiative led by Ariadne Labs and <a href="https://www.genomes2people.org/">Genomes2People</a> is doing. We are working with health systems to design a pathway to successful implementation and to offer sustainable preventive genomic screening. So far our early projects have been developed for adults in primary care, but we also know that newborn genomic screening is not far behind, as more groups around the world are tackling this issue. We are starting to explore what that implementation might look like. This unique group is made up of genetic counselors and experts in implementation, human centered design, and outcomes assessment. The PPH team is creating implementation pathways, patient and provider tools, and guides that work across various clinical contexts so that they may be accessible to any health system interested in practicing precision medicine. We are doing this to advance our mission to improve population health equitably by creating innovations and solutions that lead to widespread integration of precision medicine in healthcare and everyday life.</p><p>So, is it time for health systems to offer preventive genomic screening? We think so and we are working to help them do it!</p><p><strong><em>Carrie Blout Zawatsky</em></strong><em>, MS, CGC, is Director of Research Development and Senior Genetic Counselor with Genomes2People, Brigham and Women’s Hospital and Harvard Medical School; Associate Director of Project Management, Precision Population Health, Ariadne Labs; and Adjunct Associate Professor, MGH Institute of Health Professions.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=59b52daa8a26" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Making Genomics as Diverse as Humanity]]></title>
            <link>https://genomes2people.medium.com/making-genomics-as-diverse-as-humanity-87bdfe42ca72?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/87bdfe42ca72</guid>
            <category><![CDATA[research]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[diversity-and-inclusion]]></category>
            <category><![CDATA[inclusion]]></category>
            <category><![CDATA[genomics]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Tue, 15 Nov 2022 16:18:13 GMT</pubDate>
            <atom:updated>2022-11-18T15:13:24.664Z</atom:updated>
            <content:encoded><![CDATA[<p><em>The lack of diversity in genomic research may be a call to fundamentally change the research enterprise.</em></p><figure><img alt="Dr. Evelynn Hammonds and Dr. Robert C. Green chat via Zoom." src="https://cdn-images-1.medium.com/max/1024/1*G3F8LbBLVdsFq4-JGiyJBw.png" /></figure><p>By Robert C. Green</p><p>Medical research has a diversity problem. It happens through a combination of factors, from researchers’ own uneven recruitment practices to many communities’ mistrust of medical institutions, built both on<a href="https://www.cdc.gov/tuskegee/timeline.htm"> historical atrocities</a> and on<a href="https://www.nytimes.com/2021/08/17/health/racial-disparities-health-care.html"> present-day gaps</a> in quality of medical care. A<a href="https://doi.org/10.1038/s41572-021-00316-8"> recent review</a> of clinical trials around the globe found that 76% of participants were white and only 7% were Black. In the United States, the National Institutes of Health released a new<a href="https://www.nimhd.nih.gov/about/strategic-plan/"> strategic plan</a> in response to persistent health disparities and those same communities’ lack of representation in research.</p><p>In our own clinical trials, the<a href="https://www.genomes2people.org/"> Genomes2People</a> Research Program has been more successful than most in achieving diversity among our participants; for example, the<a href="https://www.genomes2people.org/research/reveal/"> REVEAL Study</a> on Alzheimer’s Disease risks consistently included at least 20% individuals with African ancestry.</p><p>With clinical genomics, though, we face a different set of headwinds. What’s different about genetics? Why do we find special challenges, not just for recruitment, but for the entire integration of genomics into medical science?</p><p>I had <a href="https://www.youtube.com/watch?v=kyNuRfyt9-4&amp;t=1644s">a conversation</a> earlier this year with <a href="https://histsci.fas.harvard.edu/people/evelynn-hammonds">Dr. Evelynn Hammonds</a>, Chair of the Department of the History of Science and Professor of History of Science and of African and African-American Studies at Harvard University. Dr Hammonds points out that genetics is sometimes discussed today in ways that reinscribe old ideas of genetic determinism, “the notion that there’s something fundamentally biologically different between white groups of people and Black, brown, and Asian groups of people.” We see this at times with DNA ancestry testing, sometimes misused as a way of putting people into racial and ethnic categories. It brings up echoes of the “one drop” rule of Jim Crow, in which any trace of African ancestry legally classified a person as “Negro.”</p><p>“It’s brought back a whole story that, many times in the history of medicine, we thought had been resolved.”</p><p>As Dr. Hammonds points out, historical mistrust is also kept alive by<a href="https://genomes2people.medium.com/race-ancestry-and-representation-the-role-of-genetic-medicine-870f1f051042"> ongoing disparities</a> in medical care. “Many Black and brown people walk into a medical setting with the sense that it’s just not going to turn out well. That they’re not going to be treated with the kind of care that will allow them to actually be helped by these new technologies, genetics and genomics.</p><p>“There’s a sense of skepticism: You’ve used your new technologies on us before and it hasn’t turned out well. Why should we believe you now?”</p><p>Some researchers (and practitioners) get frustrated with this; but if we are actually listening, it sounds like a call to fundamentally change the research enterprise. To take seriously the same mindset shift that led us to say “research participants” instead of “research subjects.”</p><p>I believe that an important step in this direction, especially for genomic research, is to normalize returning <a href="https://genomes2people.medium.com/how-genomic-researchers-can-save-their-participants-lives-5d49a966099e">potentially life-saving</a> research results to participants.</p><p>To many, this sounds obvious. Medical research can already feel akin to medical care, from a participant’s perspective, and we’ve heard plenty of feedback along the lines of: <em>If you find something that can save my life, I expect you to tell me about it.</em> We’ve been returning results for years in some of our own trials, including over 2,600 people through<a href="https://www.genomes2people.org/research/the-popseq-project/"> a partnership with</a> the<a href="https://www.jacksonheartstudy.org/"> Jackson Heart Study</a>. Yet returning results remains a contentious practice, especially in genomic research.</p><p>“The research <em>should</em> be given back to participants, as part of the ethics of care,” Dr. Hammonds agrees. “Particularly for populations with a long history of being used to produce new medical knowledge, but not having that knowledge actually serve them.”</p><p>Other steps are needed, too. Researchers are often resistant, even resentful, toward requirements to have a certain percentage of people of color in their research recruitment pool; at the same time, they may view the participants themselves as “resistant” to participating. Here, Dr. Hammonds makes an important distinction: Sometimes, “resistance exists because there are real, absolute barriers to participation.” She endorses the idea of paying participants to join a study, accounting for factors like transportation costs and taking time off work.</p><p>All of this overlaps with another fundamental issue, one we have also discussed in this space: “We have not solved the problem of why it’s so difficult to increase the diversity of the population of medical <em>researchers</em>.” The same can be said of related fields,<a href="https://genomes2people.medium.com/unlocking-a-cosmos-of-diversity-within-the-profession-of-genetic-counseling-b4d6218f8440"> including genetic counseling</a>.</p><p>Returning research results, however controversial, may sound like a small piece of the puzzle. It could also be the next step forward in real, impactful efforts to diversify genomic research.</p><p><a href="http://www.genomes2people.org/about/director/"><em>Robert C. Green, M.D., M.P.H.</em></a><em>, is a medical geneticist and physician-scientist who directs the </em><a href="http://www.genomes2people.org/"><em>G2P Research Program</em></a><em> in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School. Follow him on Twitter at </em><a href="https://twitter.com/RobertCGreen"><em>@RobertCGreen</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=87bdfe42ca72" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[From Researcher to Patient: Knowledge is Power]]></title>
            <link>https://genomes2people.medium.com/from-researcher-to-patient-knowledge-is-power-71c44b7d3df9?source=rss-2971ce165ddd------2</link>
            <guid isPermaLink="false">https://medium.com/p/71c44b7d3df9</guid>
            <category><![CDATA[womens-health]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[medical-research]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <dc:creator><![CDATA[Genomes2People]]></dc:creator>
            <pubDate>Sat, 15 Oct 2022 01:34:14 GMT</pubDate>
            <atom:updated>2022-10-15T01:34:14.968Z</atom:updated>
            <content:encoded><![CDATA[<p><em>I hope for a future where more people can choose to learn about their genetics and take control of their health.</em></p><p>by Charlene Preys, MS, GC</p><figure><img alt="A tattoo shows a multicolored ribbon imprinted with the ATM gene variant, above the word “Previvor.”" src="https://cdn-images-1.medium.com/max/1024/1*b_w3cuK7bWoWDYFl0qW2nA.jpeg" /></figure><p>When I began as a research trainee with the <a href="https://www.genomes2people.org/">Genomes2People</a> (G2P) research program in 2019, it never crossed my mind that I might end up at the epicenter of preventive genomic medicine as a patient myself. I have had the honor of counseling patients across various clinical specialties as a genetic counseling trainee, and worked in genetics research that empowers individuals to take control over their health based on their genetic findings. Up until a year ago, I thought I was training to become a healthcare provider, not to be a patient.</p><p>One year ago, I underwent genetic counseling and testing for hereditary cancer associated with the <em>ATM</em> gene after a family member discovered their own <em>ATM</em> status. You can read about <a href="https://medium.com/@cpreys1997/the-tables-have-turned-59508eba8fd3">this experience here</a>. The <em>ATM </em>gene is associated with breast, pancreatic, ovarian, and prostate cancers. When someone has a pathogenic variant in the gene, it increases their lifetime risk of developing one of these cancers. For me, it was important to discover my <em>ATM</em> status because of my family’s history of cancer so that I can hopefully prevent a cancer diagnosis or catch one early on.</p><p>Upon receiving my <em>ATM</em> status, my risk of developing breast cancer jumped from 12% to 40% and my risk of developing pancreatic cancer increased from &lt;1% to 10% (<a href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf">NCCN Guidelines V1.2023</a>). These percentages within the context of my family history are not just numbers. They can mean life or death. Knowing these percentages used to make me feel nervous, scared, and at times emotional. One year later, these numbers symbolize empowerment — I have knowledge that my aunts did not have when they were diagnosed with cancer.</p><p>I can do something about my risk.</p><p>When learning to cope with my cancer risk, patient organizations and support groups were vital to my healing process. Two months after learning my <em>ATM</em> status, I joined my first virtual support group on Facebook. I discovered a community of people who were living a story similar to mine, which was healing in and of itself; I found people who understood my grief and fear. I found people who could share their experiences and offer advice.</p><p>Six months later I discovered an organization called <a href="https://www.instagram.com/the_breasties/">The Breasties</a>. This organization works to connect cancer survivors, previvors, and thrivers to one another through virtual support groups and local in-person events. Their goal is to uplift the voices of people living with a looming cloud of cancer, share their stories, and build a community. Because of The Breasties, I feel seen. My emotions have been validated, and they have empowered me to see that yes, my risk is scary, but I can do something about it.</p><p>As we enter the month of October or “Breast Cancer Awareness Month,” I want to draw attention to patient support organizations that directly benefit those impacted by breast and gyn cancers. We do not need an awareness month — we need action, support, and donations that will directly benefit those affected. In addition to providing community, patient organizations often offer direct monetary support to individuals in need. <a href="https://pubmed.ncbi.nlm.nih.gov/34008086/">In a 2015 paper</a> published in The Journal of European Health Economics, authors found that a patient diagnosed with breast cancer can pay anywhere from $103,573 to $376,573 for healthcare costs per year in the United States, compared to those without a breast cancer diagnosis who pay an average of $8,019 per year. These numbers are concerning, particularly where the <a href="https://www.worlddata.info/average-income.php#:~:text=Included%20in%20this%20amount%20are,than%20in%20the%20previous%20year).">average income of a person living in the United States</a> is just shy of $75,000 per year. Organizations such as The Breasties connect patients, survivors, and previvors to scholarship and funds to help alleviate the costs associated with treatment and prevention.</p><p>I challenge readers to reconsider purchasing a t-shirt with a pink ribbon on it at the store, or a pink lanyard. Consider donating to <a href="https://breastcanceraf.org/donate/">The Breast Cancer Assistance Fund</a>, <a href="https://www.genshelpinghands.org/support-our-programs.html">Genevivie’s Helping Hands</a>, <a href="https://forthegiftofhope.org/donate/">The Gift of Hope</a>, <a href="https://pinkfund.org/get-involved/donate-now/">The Pink Fund</a>, or the <a href="http://www.sistersnetworkinc.org/donations.html">Sisters Network Breast Cancer Assistance Fund</a> instead. If monetary support is not within your own reach, connect with these organizations to offer assistance to individuals in other ways! Cooking a meal, taking care of household tasks, or running an errand is just as impactful as a monetary donation.</p><p>As I reflect on the last year, I am grateful. My <em>ATM</em> status has given me access to cancer prevention, screening at 25 years young, and an oncologist that I would not have otherwise. Preventive healthcare works. Now, as a patient and genetic counselor, I support the mission of <a href="https://www.genomes2people.org/">G2P</a> more than ever. Offering whole genome sequencing for individuals without a personal or family medical history of hereditary disease may seem extreme, but our <a href="https://www.genomes2people.org/wp-content/uploads/2018/07/20170627_MedSeq_AnnalsInternalMedicine_Vassy_WGSPrimaryCare.pdf">MedSeq</a> and <a href="https://www.genomes2people.org/wp-content/uploads/2018/11/20190101_BabySeq_AJHG__Ceyhan-Birsoy_InterpretationGS.pdf">BabySeq</a> studies show that 10–15% of ostensibly healthy people harbor a pathogenic finding that can directly impact the care they receive. We call these medically actionable results, where an individual discovers they have a variant in a gene where preventive screening, or treatment exists. For many reasons, individuals may not want this information, but if we can offer it, why not do so?</p><p>I hope for a future where more people can choose to learn about their genetics and take control of their health. I have found comfort and empowerment in my journey and hope that more people can too.</p><p><a href="https://www.linkedin.com/in/charlene-preys/"><em>Charlene Preys, MS, GC</em></a><em>, has been a Clinical Research Assistant with Genomes2People since 2020.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=71c44b7d3df9" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>